(NASDAQ: VYNE) Vyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.06%.
Vyne Therapeutics's earnings in 2025 is -$38,545,000.On average, 3 Wall Street analysts forecast VYNE's earnings for 2025 to be -$20,887,175, with the lowest VYNE earnings forecast at -$25,217,443, and the highest VYNE earnings forecast at -$14,773,856. On average, 2 Wall Street analysts forecast VYNE's earnings for 2026 to be -$21,523,979, with the lowest VYNE earnings forecast at -$28,019,382, and the highest VYNE earnings forecast at -$15,028,577.
In 2027, VYNE is forecast to generate -$16,302,186 in earnings, with the lowest earnings forecast at -$16,302,186 and the highest earnings forecast at -$16,302,186.